蔚蓝生物(603739) - 2019 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 49.83% to CNY 4,088,988.77 compared to the same period last year[6]. - Operating revenue decreased by 3.49% to CNY 173,470,991.55 compared to the previous year[6]. - The company’s basic earnings per share decreased by 22.22% to CNY 0.07[6]. - Total revenue for Q1 2019 was ¥173,470,991.55, a decrease of 3.5% compared to ¥179,741,149.13 in Q1 2018[29]. - The company's operating revenue for Q1 2019 was ¥13,139,969.84, a decrease of 34.5% compared to ¥20,055,706.67 in Q1 2018[32]. - Net profit for Q1 2019 reached ¥12,251,238.34, an increase of 8.2% from ¥11,317,401.13 in Q1 2018[30]. - The net profit for Q1 2019 was ¥1,774,087.09, a significant improvement from a net loss of ¥3,566,918.08 in Q1 2018[33]. - The total comprehensive income for Q1 2019 was ¥1,774,087.09, recovering from a total comprehensive loss of ¥3,566,918.08 in the same period last year[33]. Assets and Liabilities - Total assets increased by 30.43% to CNY 1,232,970,147.89 compared to the end of the previous year[6]. - The total assets as of March 31, 2019, amounted to 1,232,970,147.89, compared to 945,321,200.81 on December 31, 2018[22]. - The company's total assets as of March 31, 2019, amounted to ¥1,040,175,139.83, up from ¥698,953,536.66 at the end of 2018[27]. - Total current assets increased to ¥698,729,219.01 in Q1 2019, compared to ¥357,157,174.84 in Q4 2018[26]. - The total liabilities decreased from 313,944,300.80 to 237,110,001.20, reflecting a reduction in short-term borrowings[22]. - Total liabilities decreased to ¥293,421,785.50 in Q1 2019 from ¥309,280,437.92 in Q4 2018[27]. - Total equity reached CNY 631,376,900.01, including CNY 418,862,039.71 in undistributed profits[43]. - The total equity attributable to shareholders of the parent company was CNY 569,693,159.34[43]. Cash Flow - Cash flow from operating activities improved by 60.79%, reaching CNY -23,372,643.57[6]. - The net cash flow from operating activities improved by 60.94%, increasing from -59,836,256.01 to -23,372,643.57[15]. - The net cash flow from investing activities surged by 1350.60%, from -13,592,555.60 to -197,173,779.44, primarily due to increased investment of idle funds[15]. - The net cash flow from financing activities increased significantly by 668.14%, from -53,716,793.73 to 305,184,148.91, mainly due to funds raised from new stock issuance[15]. - Cash flow from operating activities showed a net outflow of ¥23,372,643.57 in Q1 2019, an improvement from a net outflow of ¥59,612,256.01 in Q1 2018[34]. - The company reported cash inflow from financing activities of ¥363,183,534.80 in Q1 2019, compared to ¥28,500,000.00 in Q1 2018[35]. - The net cash flow from financing activities was CNY 307,780,226.61, a substantial improvement from -CNY 26,277,100.00 in the previous year[38]. Expenses - The company’s gross profit margin was impacted by a 1.07% increase in operating costs, totaling CNY 93,705,617.64[13]. - Management expenses increased by 11.14%, from 18,454,614.46 to 20,510,271.91, mainly due to costs related to new stock issuance[14]. - Financial expenses decreased by 31.41%, from 2,046,391.96 to 1,403,528.11, primarily due to reduced foreign exchange losses[14]. - Research and development expenses for Q1 2019 were ¥16,521,013.01, slightly up from ¥16,352,269.11 in Q1 2018[30]. - The company incurred a total operating cost of ¥8,312,600.46 in Q1 2019, down from ¥15,342,093.28 in Q1 2018[32]. Shareholder Information - The number of shareholders reached 21,321, with the largest shareholder holding 51.91% of the shares[10]. - The company received government subsidies amounting to CNY 8,507,624.21, closely related to its normal business operations[7]. - Other income rose by 43.21%, from 2,449,218.86 to 3,507,624.21, attributed to government listing incentives received[14]. - The company plans to continue expanding its market presence and investing in new product development[28]. Accounting Standards - The company adopted new financial instrument standards effective January 1, 2019, impacting the classification and measurement of financial assets[16]. - The company adopted new financial accounting standards effective January 1, 2019, impacting the reporting of financial instruments[43].